Amid a push to bolster antibiotic manufacturing in the U.S., a facility that closed last year due to bankruptcy has been reopened by new ownership, which hopes to jump-start production and meet nationwide demand for a widely prescribed treatment.
Jackson Healthcare expects the USAntibiotics plant in Bristol, Tenn., to produce 300 million capsules and 2 billion tablets of amoxicillin and its variants annually, and stockpile a five-year supply for the U.S. Amoxicillin, a member of the penicillin family, makes up about one-third of all antibiotics prescribed in the U.S. each year.
This blog is for information purposes only. The content is not intended as medical advice, diagnosis, or treatment. Should you have a medical or dermatological problem, please consult with your physician. None of the information or recommendations on this website should be interpreted as medical advice.
All product reviews, recommendations, and references are based on the author’s personal experience and impressions using the products. All views and opinions are the author’s own.
This blog post may contain affiliate links. An affiliate link means we may earn a commission if you click on a link and make a purchase, without any extra cost to you.
Please see our Disclaimer for more information.